Jeffrey S. Turner - Concepedia

Author

Jeffrey S. Turner

Oncology Specialists

Also Known As

J. S. Turner, Jeffrey S. Turner, Jeffrey Turner

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Oncology Specialists

About

Jeffrey S. Turner is an author at Oncology Specialists specializing in medicine, cancer research, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	248
2	Immunology	3	3	238
3	Pharmacology	3	3	41
4	Health Sciences	1	1	14
5	Cancer Therapeutics	1	1	14

Jeffrey S. Turner

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Activities of LL-37, a Cathelin-Associated Antimicrobial Peptide of Human Neutrophils Jeffrey S. Turner, Yoon Cho, Nhu-Nguyen Dinh, Antimicrobial Agents and Chemotherapy	1998	787
Evaluation of the Inactivation of Infectious Herpes Simplex Virus by Host-Defense Peptides Bushra Yasin, Mabel Pang, Jeffrey S. Turner, European Journal of Clinical Microbiology & Infectious Diseases VaccinationViral PersistenceHost-defense PeptidesImmunologyViral Pathogenesis	2000	207
Activity of Protegrins against Yeast-Phase <i>Candida albicans</i> Yoon Cho, Jeffrey S. Turner, Nhu-Nguyen Dinh, Infection and Immunity	1998	69
Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer Mark C. Scholz, Sabrina Yep, Micah Chancey, ImmunoTargets and Therapy	2017	57
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer Jeffrey S. Turner, Uzair B. Chaudhary Anti-Cancer Drugs UrologyActive Hemicellulose CompoundMedicineHerbal MedicineImmunology	2009	17
Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC). Justine Ku, Kirk Wilenius, Claire Larsen, Journal of Clinical Oncology Cancer ManagementImmunologyCastrate-resistant Prostate CancerPharmacotherapyImmunotherapeutics	2018	14
Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer. Fábio Almeida, Chi‐Kwan Yen, Mark C. Scholz, PubMed	2017	12
Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone. Mark C. Scholz, Richard Y. Lam, Jeffrey S. Turner, Journal of Clinical Oncology Preclinical TherapeuticsFda ApprovalPharmacotherapyPsa ResponsePre-clinical Pharmacology	2014	10

Page 1